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ABSTRACT
Recent prospective studies in which relatives of patients with dilated
cardiomyopathy (DCM) have been screened for the disease using
echocardiography have documented a familial prevalence of 20-25%. Those
asymptomatic relatives with left ventricular enlargement (LVE) are assumed to
have early familial DCM. A serum marker which could identifyfamilies at risk of
developing dilated cardiomyopathy should be of use in screening for the disease.
Alcohol has been implicated as a risk factor for DCM but a causal relationship
has not been established.
This study was designed to: (i) compare HLA distribution in familial and
non-familial dilated cardiomyopathy; (ii) histologically evaluate myocardial
biopsy specimens obtained during diagnostic workup in relatives with
echocardiographic LVE; (iii) determine the association between alcohol
consumption and DCM, by comparing a cohort ofwell defined DCMpatients with
randomly selected, population-based controls.
Methods and Results We report on a group of 100 patients with dilated
cardiomyopathy. Two hundred first-degree relatives from 56 of these proband
families were screened for dilated cardiomyopathy by echocardiography. The
HLA profile of the patients with dilated cardiomyopathy, as well as ofthe familial
and non-familial subgroups, was compared with that of 9000 normal controls.
The familial prevalence of dilated cardiomyopathy in this patient group was
'definite' in 14 / 56 (25%) and 'possible' in 25 / 56 (45%). The HLA-DR4
frequency was similar in the 100 patients with dilated cardiomyopathy as
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compared with the 9000 controls (39% v 32%; NS). However, the DR4 subtype
was significantly more common in the 25 probands with a familial tendency to
dilated cardiomyopathy than the 31 probands with non-familial dilated
cardiomyopathy (68% v 32%; P < 0.05).
The first 5 relatives demonstrating echocardiographic asymptomatic DCM
underwent cardiac catheterization to confirm LVE with normal coronary
angiography. Histological evaluation of right ventricular myocardial biopsy
specimens obtained included H+E and TUNEL staining, and CPP-32 and HLA-
DR expression. The apoptotic index was calculated as the number ofpositive-
staining cells divided by total number ofnucleated cells (%) in ten separate high
power fields per case. In all cases, mild to moderate myocyte hypertrophy was
observed with only mild or no interstitial fibrosis. There was no evidence of
inflammation. The apoptotic index ranged from 17-30% (mean=25%o). TUNEL
positive cells were more prominent in the interstitium than the myocardium and
were associated with high levels of CPP-32 immunoreactivity. HLA-DR
expression was detected in all cases and was again more pronounced within the
interstitium.
Questionnaires were administered detailing average weekly intake of
alcohol, total lifetime consumption and alcohol abuse in cases and controls.
Significantly more of the 100 patients with DCM than the 211 controls drank
greater than the recommended weekly intake of alcohol (40% vs. 24%; P<0.01)
and were alcohol abusers according to the CAGE questionnaire (27% vs. 16%;
P<0.05). The average total lifetime consumption measured in units ofalcohol was
also significantly greater in cases than controls (31,200 vs. 7,904; P<0.01).
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Conclusions The present finding supports an HLA-linked predisposition to
familial dilated cardiomyopathy. The HLA-type DR4 was significantly more
common in familial than non-familial cases. More importantly, the DR4 halotype
was associated with two-thirds of the families at riskfor dilated cardiomyopathy.
This study demonstrates for the first time that asymptomatic relatives, of DCM
patients, with echocardiographic LVE have abnormal cellularity. The disease
activity does not appear to be inflammatory but is associated with a high
apoptotic index. The study also confirms previous suspicion of a causal
association between alcohol and DCM, with significantly more patients than





Specific diseases of the heart muscle were recognised as early as 1933 (1) and the
concept of primary myocardial disease was put forward by Mattingly in 1959 (2).
It was Harvey in the United States (3) and Goodwin in the United Kingdom (4)
who shortly after this called the disease "cardiomyopathy".
Idiopathic dilated cardiomyopathy (DCM) was defined as global
ventricular dilatation with impaired systolic function in the absence of a known
cause (5). In view of the large amount of ongoing research in the field, the
definition has since been expanded to say that DCM "may be familial/genetic,
viral and/or autoimmune or alcoholic/toxic" (6). The diagnosis classically
excludes patients with known cause for heart muscle disease, e.g. coronary artery
disease, hypertension, valvular and congenital heart disease, as well as infective
(myocarditis) and metabolic (thyroid disease) causes. The usual method of
diagnosing DCM is by echocardiography, to assess ventricular size and function.
Echocardiography is also the most useful test for screening and follow-up of
patients with DCM. To be certain of the diagnosis one must perform coronary
angiography, to exclude coronary artery disease. Endomyocardial biopsy may be
performed but is fairly unhelpful as the findings are non-specific.
DCM most commonly presents in young and middle-aged men. Patients
are probably asymptomatic for years and tend to present with symptoms of heart
failure and less commonly systemic embolism, chest pain, arrhythmias or sudden
cardiac death. Some patients die in heart failure but most deaths are sudden and
presumed to be secondary to ventricular arrhythmias.
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INTRODUCTION
As with other forms of cardiomyopathy, DCM may have a genetic link and
be inherited in certain individuals. Triggers thought to be associated with DCM
include viral illness and alcohol. The general hypothesis being that such
environmental triggers may induce an autoimmune response, through aberrant
major histocompatability antigen expression, in a genetically susceptible
individual.
The role of viral infection in the pathogenesis of DCM has been supported
largely by looking at enteroviral serology and RNA persistence in patients with
DCM. Higher neutralising antibodies against coxsackievirus B were found in
DCM patients than controls, with titres being more elevated in those with recent
onset of disease (7). A study of transplanted hearts in patients with end-stage
DCM found enteroviral RNA in 6 / 21 (29%), as compared to 1 /17 (6%) of
patients transplanted for ischaemic heart disease (8). This evidence suggested that
persistence enteroviral infection may be involved in the pathogenesis of some
cases of DCM. The possible aetiological role of enteroviruses was further
supported by the detection of enteroviral RNA in myocardial biopsy specimens. In
a group of 120 patients with heart muscle disease due to myocarditis or DCM, 41
(34%) demonstrated the presence of myocardial enteroviral RNA (9). Only 16
(13%) of the patients described a history of preceding viral illness, underscoring
the underestimation of viral illness obtained through history-taking alone.
Interestingly, in this study, the presence of enteroviral RNA within the
myocardium at initial diagnosis was independent predictor of outcome over a
mean follow-up period of 25 months. It is conceivable that such viral persistence
may initiate a secondary, immune-mediated response, leading to an accentuated
decline in ventricular function in a susceptible individual.
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INTRODUCTION
The relationship between enteroviral persistence and myocardial damage
in patients with DCM was strengthened by the finding that enteroviral RNA
sequences were present in myocardial biopsy specimens from 4/16 (25%) patients
who were positive for antimyosin uptake (a marker of myocardial cell damage),
compared to 0/3 patients with negative antimyosin scans (10). Although the
majority of patients in study (84%) had positive antimyosin scans, only a minority
(25%) also showed evidence of persistence enteroviral infection. Thus, implying
that the myocardial damage observed in DCM patients is probably the end result
of variety of infectious (viral) and non-infectious (alcohol) agents. The damage
caused by these agents may be perpetuated by the production of cardiac
autoantibodies in a susceptible individual. Post-viral autoimmune heart disease
remains an attractive aetiological concept for the pathogenesis of DCM and
myocarditis. However, the interpretation of viral screening is hampered by the
high prevalence of the proposed environmental agent in the general population.
This problem was addressed by comparing the frequency of antibodies to
Coxsackie B in a group of patients with DCM with that of environmentally-
matched controls. When these two groups were studied prospectively over the
same time period, no difference in the frequency of positive viral serology was
observed (11). Hence, it remains true to say that in the vast majority of patients,




Estimates concerning the epidemiology of DCM are based on the
landmark population-based study from Olmsted County (13). Using the unique
records linkage system of the Mayo Clinic and the Rochester Epidemiology
Project, diagnostic data on the entire population of Olmsted County, Minnesota
were accessed. From 1975 to 1984, 45 new cases of DCM were identified. The
age- and sex-adjusted incidence and prevalence rates ofDCM in the United States
were, hence, calculated at 6.0 and 36.5 per 100,000 person-years and 100,000
population, respectively. The frequency in an Irish population is unknown. By
extrapolation from US data, there are approximately 2000 cases prevalent in
Ireland with about 200 new cases annually. DCM accounts for 50% of the cardiac
transplantations performed in Ireland.
Early, retrospective studies on the natural history of DCM indicated
median and five year survivals of around 20% and 50% respectively (14,15).
However, recent work has demonstrated that the prognosis is more favourable
when referral bias is taken into account by comparing hospitalised patients with a
population-based cohort (16). Earlier diagnosis and better treatment (ACE
inhibitors and beta-blockers, see below) for patients with DCM have contributed
to the observed improvement in the prognosis in the last two decades (17,18). The
five year survival for patients diagnosed in the 1990's may be as high as 80% (18).
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TREATMENT OF DCM
Death in patients with DCM usually occurs as a consequence of ventricular
arrhythmia or progressively worsening heart failure. The ultimate goals of
pharmacological treatment are, therefore, prevention of lethal arrhythmias and
control of left ventricular dysfunction. Routine anti-arrhythmic therapy in patients
with DCM has been disappointing. Anti-arrhythmic treatment, guided by
electrophysiological study, can improve prognosis in those patients with sustained
and inducible ventricular arrhythmias (19,20) and those who present with
predominantly right ventricular disease (21). Angiotensin-converting enzyme
(ACE) inhibitors, discussed below, may also have a direct electrophysiological
anti-arrhythmic effect (22,23) .
Digoxin appears to be of symptomatic benefit to patients with non-
ischaemic and ischaemic cardiomyopathy, even when their heart failure is
clinically mild and they remain in sinus rhythm (24-26). The use of diuretics, for
relief of symptoms of heart failure, and warfarin, for prevention of
thromboembolism, have little impact on survival or progression of disease.
Cardiac transplantation has been shown to improve prognosis with a one-year
survival of greater than 80% but is limited to a minority by organ availability
(27,28).
P-blockers were first introduced as a treatment for patients with DCM
twenty years ago. Metoprolol has beneficial clinical and haemodynamic effects in
DCM which are thought to be related to: decrease in myocardial oxygen demand;
decrease in circulating catecholamines; up-regulation of (3-receptor density;
prevention of sudden cardiac death by anti-arrhythmic activity (29-31).
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TREATMENT OF DCM
Recent trials with carvedilol, a P-blocker with vasodilator properties
related to concomitant a-blockade, show promise in patients with DCM both in
terms of symptom relief and reduced mortality (32). A recent meta-analysis of the
randomised trails looking at the effect of P-blockade on mortality in patients with
heart failure, demonstrated an all-cause mortality benefit, with an impressive
overall decrease in the odds of death of 31% and one death prevented for every 35
patients treated (33). This benefit was similar for patients with ischaemic and non-
ischaemic cardiomyopathy and there was a trend towards a greater survival benefit
with carvedilol compared to P-blockers without a-blocking activity. Similarly,
low dose amiodarone may reduce mortality from heart failure and arrhythmia in
non-ischaemic dilated cardiomyopathy (34-36).
The degree of left ventricular dysfunction in patients with ischaemic heart
disease is known to correlate highly with mortality (37,38). Treatment with ACE
inhibitors can reduce the degree of ventricular enlargement and remodelling in the
post-myocardial infarction setting (39). ACE inhibitors not only attenuate left
ventricular remodelling but also directly inhibit the deleterious effects of neuro-
hormonal activation in chronic heart failure (40) and have anti-arrhythmic activity
(22,23). Since this earlier work looking at the role of ACE inhibition, many well-
constructed, randomised and controlled trials have confirmed their benefit in
improving the outlook of patients with left ventricular dysfunction after
myocardial infarction (41-47). There is no reason to suppose that ACE inhibitor
therapy does not similarly benefit patients with DCM.
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TREATMENT OF DCM
A recent randomised study looking at the role of immunosuppressive
therapy for patients with myocarditis did not support routine treatment with
prednisolone and cyclosporin or azathioprine (48). The patients were, however,
identified retrospectively over the preceding two years by the results of
endomyocardial biopsy. This trial does not rule out a benefit for selected patients
at the time of diagnosis. If a marker could be found to predict those patients at
risk, from an inadequate immune response or an autoimmune response, early on in
the course of the illness then progressive myocardial damage could theoretically
be prevented by timely immunosuppression.
In summary, there are many pharmacological therapeutic strategies of
possible symptomatic and survival benefit for patients with DCM. The greatest
benefit is achieved for those patients diagnosed early, before the disease and its
concomitant ventricular dysfunction are well advanced. Any screening test to
identify groups at risk of developing DCM would of course be of use for earlier
diagnosis and treatment. By better understanding the aetiology ofDCM, one may
pin-point such at risk groups and advise them on preventative and follow-up
measures.
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THE AUTOIMMUNE HYPOTHESIS: HLA-DISTRIBUTION
There are two basic stages in the development of an autoimmune disease. Namely,
the creation of the autoantibody followed by tissue damage due to the immune
reaction (49). Both long-term humoral and cell-mediated immune responses
involve the association of T cells with class II major histocompatability antigens,
i.e. HLA-DR. The expression of these DR antigens is usually limited to the
immune system and vascular endothelial cells. When DR expression occurs in
tissue where it does not normally exist, subsequent T cell activation leads to an
autoimmune reaction. This autoimmune activity can also be detected by the
presence of unusually high concentrations of organ-specific autoantibodies in the
serum, which can maintain tolerance to the ongoing autoimmune response.
Autoimmune disease may be initiated through T cell activation by viruses
(discussed above) or other environmental factors, leading to an immune response
directed against those self-cells which are aberrantly expressing DR antigen. The
linkage of HLA-DR halotypes with various autoimmune disease entities, thus
points to a genetic predisposition to respond to such environmental triggers by
developing an organ-specific immune response.
The most popular hypothesis regarding the aetiology of DCM is an
autoimmune, inherited predisposition initiated by an environmental trigger, e.g.
viral illness or alcohol. This theory has been lent support by an increased
frequency of HLA-DR4 (50) and the presence of circulating cardiac
autoantibodies (51,52) in some patients with DCM. The detection of disease
specific cardiac autoantibodies also implies autoimmune involvement in DCM,
with anti-a-myosin antibodies have been detected more frequently in subsets of
patients than in controls (53).
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THE AUTOIMMUNE HYPOTHESIS: HLA-DISTRIBUTION
The majority of DCM patients, however, do not show evidence of
autoimmunity in the form of increased frequency of HLA-DR subtypes, enhanced
tissue expression of DR antigens or high levels of circulating organ-specific
autoantibodies. In these cases, the disease is hypothesized to be non-autoimmune
and perhaps solely initiated by an infectious (viral) or toxic (alcohol) agent.
Alternatively, serological evidence of autoimmunity may be present only in the
early stages of the disease process. In any case, it would seem appropriate to direct
any immunotherapy, aimed at slowing or reversing this disease process, at those
patients identified as having an ongoing immune reaction to their own
myocardium.
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THE AUTOIMMUNE HYPOTHESIS: FAMILIAL PREVALENCE
The first prospective studies in which relatives of patients with DCM were
screened for the disease by echocardiography were reported recently and gave a
familial prevalence of 20-25% (54,55). It is appealing to suggest that the familial
tendency for DCM in these patients is linked with a genetic predisposition to
develop an autoimmune response to the putative environmental triggers. By
screening family members one may potentially identify latent forms of the
disease, with actively ongoing autoimmune activity and less severe left ventricular
impairment. It is not unreasonable to suspect that such patients may respond better
to treatment in the forms of immunotherapy and/or vasodilators and have an
improved prognosis secondary to this early detection of the DCM disease state.
The presence of autoantibodies does not adequately distinguish between
familial and non-familial DCM (51,52). We postulated that the DR4 subtype
might identify families at risk of developing DCM, who would be most likely to
benefit from periodic screening with echocardiography and early treatment when
left ventricular dysfunction is detected.
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EARLY FAMILIAL DCM: HISTOLOGICAL EVALUATION
Prospective studies in which relatives of patients with DCM were screened by
echocardiography have consistently demonstrated a familial prevalence of 25%.
Screening can potentially identify latent forms of the disease which may respond
better to treatment with an improvement in prognosis. Echocardiographic
screening of asymptomatic relatives of DCM patients identifies a subset with left
ventricular enlargement (LVE) who are assumed to have early familial DCM.
Histological evaluation of explanted hearts of patients with end-stage
DCM has revealed myocyte apoptosis (56,57). However, there is little evidence on
the presence or role of apoptosis in early (pre-clinical) DCM and some have
hypothesized that early DCM may indeed be primarily an interstitial disease. We
report the results of myocardial biopsy specimens obtained during diagnostic
workup in asymptomatic relatives with echocardiographic LVE.
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ALCOHOL CONSUMPTION
By definition the cause of DCM is unknown. Alcohol has been implicated as a
risk factor for DCM but a causal relationship has not yet been established. The
frequently reported relationship between alcoholism and heart failure has lead to
alcohol being postulated as a cause ofDCM (14,58). However, many patients with
DCM drink alcohol within recommended limits, i.e. are not alcoholics.
Nevertheless, alcohol is often cited as the cause of their DCM in a clinical setting.
The aetiological role of alcohol in dilated cardiomyopathy continues to be
debated. Twenty years ago Oakley explained that acute myocardial depression by
alcohol and improvement of ventricular function after alcohol withdrawal offered
no proof of causation (59). In her own words: "Recognizing that a murder has
been committed does not necessarily help to identify the criminal." The evidence
linking alcohol consumption with chronic left ventricular failure remains
circumstantial and conflicting. Teragaki et al found no correlation between
lifetime alcohol intake and cardiac function in men with a history of excessive
consumption and congestive heart failure (60). They commented that the amount
alcohol required to cause ventricular dysfunction remains unclear. Any stated
level above which congestive heart failure is attributed to alcohol abuse is purely
arbitrary and, also, does not exclude the possibility of a causative role for alcohol
at levels that would be considered socially acceptable in subjects without heart
failure.
Marquez et al performed echocardiography on a group of asymptomatic
men and women with a diagnosis chronic alcoholism (61). Using the accepted
diagnostic criteria, i.e. an end-diastolic diameter more than two standard above the
mean and an ejection fraction less than 50%, only 14% of the men and 12% of the
women had dilated cardiomyopathy.
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ALCOHOL CONSUMPTION
Each patient had reported drinking at least 70 units of alcohol per day in the
previous two years. Nevertheless, the vast majority of these patients did not
exhibit heart muscle disease.
The concepts of alcoholic heart muscle disease and/or alcohol-induced
autoimmune dilated cardiomyopathy are attractive but lacking in definitive proof.
The conclusion being, as for the evidence of a viral aetiology, that the vast
majority of patients with a diagnosis of DCM are not alcohol abusers. To
differentiate a group of patients with DCM on the basis ofweekly or total lifetime
consumption of alcohol and give them an alternative diagnosis of alcoholic heart
muscle disease (AHMD) is a gross simplification. The clinical and pathological
findings in patients diagnosed with DCM or AHMD are identical. Only a minority
of long-term alcohol abusers, as defined by reported consumption or proven
questionnaires, have evidence of left ventricular dysfunction. To make a diagnosis
of AHMD in a patient who has dilated cardiomyopathy and is also an alcohol
abuser assumes a link for which there is little evidence. The question is why do
only minority of alcohol abusers develop left ventricular dysfunction? It would
seem logical to assume that this minority is somehow sensitised to its toxic effects
and, therefore, represent another subgroup of genetically predisposed DCM
patients that have been exposed to an environmental trigger.
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ALCOHOL CONSUMPTION
No study to date has compared the alcohol intake of a cohort of DCM
patients with that of randomly selected, population-based controls. Two previous
groups from France have performed case-control studies of alcohol consumption
in DCM (62,63). However, the controls were hospital-based, with associated
potential for bias and over-matching for the putative risk factor. This study was
designed to determine the association between alcohol consumption and DCM,
thus providing important information with regard to the aetiology of DCM and the
potential for prevention of this disease.
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OBJECTIVES
In summary, the objectives of this study were to:
i) determine the frequency of familial DCM in a group ofpatients with DCM in
Ireland, by performing echocardiographic screening on all available
asymptomatic first-degree relatives;
ii) determine the distribution ofHLA-types in patients with familial and non-
familial DCM, and compare this distribution with that of normal controls;
iii) histologically evaluate myocardial biopsy specimens obtained during
diagnostic workup in relatives with echocardiographic LVE;
iv) determine the relationship between alcohol consumption and dilated
cardiomyopathy, by comparing a cohort ofwell defined DCM patients with






For the purpose of the study, patients with DCM attending the National Cardiac
Centre at the Mater Misericordiae Hospital and their first-degree relatives were
invited to attend a special clinic. To date 100 probands with DCM have been seen
at the clinic. The echocardiographic criteria for the diagnosis of dilated
cardiomyopathy were a left ventricular ejection fraction less than 50% and a left
ventricular end-diastolic dimension more than two standard deviations above the
mean, corrected for the patient's age and body surface area (64) (Appendix 1, page
80).
All the patients had angiographically normal coronary arteries. Patients
with a known cause for heart muscle disease e.g. coronary artery disease,
hypertension, valvular and congenital heart disease, as well as infective
(myocarditis) and metabolic (thyroid disease) causes were excluded. Patients with
a history of excessive alcohol consumption were included since they may have a
genetic predisposition to develop DCM.
The patients with DCM were contacted and asked to attend for history
taking, physical examination and investigation (Appendix 2, page 81). Past
medical history was elicited with regards to possible risk factors for development
of DCM, e.g. a viral illness in the three months preceding the diagnosis, a
peripartum diagnosis, atopy and cigarette smoking.
HLA typing which included class I (HLA-A, B) and class II (HLA-DR)
was performed at the National Blood Transfusion Service, using the serological
microtoxicity method. The HLA distribution in patients was compared with a




Two-dimensional, M-mode and Doppler echocardiographic examinations were
performed in the left lateral position by a single experienced operator on all
patients. The machine used was a Hewlett Packard Sonos 1500 with a 2.5 MHz
transducer. In keeping with convention, end-systolic and end-diastolic cavity
dimensions, wall thickness and fractional shortening were measured by M-mode
at a level just caudal to the tip of the mitral valve. End-diastole measurements
were taken at the R wave using the leading edge method and ejection fractions
were calculated using the cubed assumption (64). Echocardiography was
performed by a single experienced technician. M-mode left ventricular
measurements were taken from paper and checked by CMcK and HMcC to
combat inter-observer bias.
FIRST-DEGREE RELATIVES
To date, 200 first-degree from 56 proband families have attended for
echocardiography (Appendix 3, page 82). The disease was considered to be
familial if at least one first-degree relative was diagnosed as having DCM, as
defined above. If a first-degree relative fulfilled only one of the criteria for the
diagnosis of DCM, i.e. a left ventricular ejection below 50% or a left ventricular
end-diastolic dimension more than two standard above the mean, they were
entered in a "possible" category for further follow-up. Inter-observer bias was
counteracted as for probands. Also, those relatives demonstrating left ventricular
enlargement underwent repeat echocardiography approximately 6 months later to
check for intra-patient and intra-observer variability. Any families with a history
of premature sudden death (unexplained at an age of less than 50 years within 4
hours of the onset of symptoms) were also included in the "possible" category.
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HISTOLOGICAL EVALUATION OF BIOPSY SPECIMENS
The first 5 relatives demonstrating consistent LVE by echocardiography
underwent diagnostic workup including right and left cardiac catheterization, and
right ventricular myocardial biopsy (x5). Endomyocardial biopsy specimens were
formalin-fixed and wax-embedded. Subsequent histological evaluation included
haematoxylin and eosin and TUNEL staining, detection of protease CPP-32
immunoreactivity and HLA-DR expression.
DETECTION OF APOPTOTIC CELLS
The apoptotic cells were TUNEL stained using a Boehringer Mannheim In-Situ
Cell Death Detection Kit. Briefly, the slides were deparaffmized, transferred to
xylene and then rehydrated through a graded series of alcohols. The slides were
rinsed in phosphate buffered saline (PBS, 138 mM sodium chloride, 2.7 mM
potassium chloride, Sigma chemical) and treated with proteinase K (25pg/ml,
Boehringer Mannheim) for 20 minutes at 37°C, before being rinsed again in PBS.
The TUNEL reaction mixture, plus 2% normal swine serum (NSS, Vector
laboratories), was applied to the slides. They were then coverslipped and
incubated in humidity trays at 37°C for 60 minutes and rinsed in PBS. The AP-
converter (diluted to 1:5, in lOOmM tris-ElCL and 150 mM NaCL at a pH of 7.5)
was applied to the slides. They were then incubated for a further 30 minutes at
37°C and rinsed again in PBS. Slides were washed in buffer C (100 mM sodium
chloride, 100 mM tris-base, 14.85 mM magnesium chloride, pH 9.5, Sigma).
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DETECTION OF APOPTOTIC CELLS
Nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate p-toluidine
salt (Gibco BRL) color development was performed with a maximum
development time of 12 minutes. The slides were counterstained with Nuclear
Fast Red (Sigma Chemical), dehydrated and coverslipped. The addition of the
NSS reduced non-specific labeling and the dilution of the converter-AP raised the
specificity of the staining and reduced background staining. The apoptotic index
was calculated as the number of positive-staining cells divided by total number of
nucleated cells (%) in ten separate high power (x40) fields per case.
DETECTION OF PROTEASE CPP-32 AND HLA-DR EXPRESSION
After deparaffmization and rehydration, the slides were incubated with 5% normal
goat serum (Dako) for 10 minutes at room temperature. The primary antibody
(mouse monoclonal anti-CPP-32 antibody (Transduction Laboratories) or rabbit
anti-HLA-DR antibody (Zymed)) was diluted in 1% normal goat serum and
incubated overnight at 4°C in a humidity chamber. Next, the primary antibody was
rinsed off and the biotinylated secondary antisera cocktail (goat anti-mouse or
anti-rabbit IgG (Dako)) diluted to 1:400 was incubated on the slides for 30
minutes at room temperature. Streptavidin-horseradish peroxidase (Dako) and 1%
normal goat serum were applied, before incubation for 30 minutes at room
temperature. The slides were color developed in 3-amino-9-ethylcarbazole
substrate solution (Sigma) for 15 minutes at room temperature. Counterstaining in
haematoxylin was performed for 30 seconds and coverslip applied.
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ALCOHOL CASE-CONTROL STUDY
The relationship between alcohol and DCM was evaluated in a case-control study,
cases being identified as described above. Population-based controls were selected
by RANSAM (65). This is a computer-based system for drawing random samples
from the Electoral Register in Ireland. The system is updated each year from the
most recent Register and permits a random selection on a National level.
RANSAM has been used to select samples for numerous studies and shown to
produce estimates which correspond well on variables including age, sex and
occupational status. The response to the questionnaire was expected to be of the
order of 30% and a ratio of 2:1 controls to cases was deemed necessary for
statistical power. Therefore, a sample size of 600 was selected.
Patients and controls had a questionnaire filled in regarding their alcohol
intake (Appendices 4+5, pages 83-84). The questionnaire detailed the total
duration of alcohol intake in years and the average weekly consumption in units.
It also accounted for any change or cessation in alcohol intake over the years.
From these replies, the total lifetime consumption of alcohol in units was
estimated. Reported alcohol consumption was compared with the validated CAGE
questionnaire with a high sensitivity, specificity and negative predictive value for
excess alcohol intake and alcoholism (66).
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ALCOHOL CASE-CONTROL STUDY
The questionnaire was administered to patients at their clinic visit. For
practical purposes the controls were posted the same questionnaire as for the
DCM patients regarding their alcohol intake, to be completed and returned
anonymously in a stamp-addressed envelope. For statistical analysis, patients and
controls were divided into three basic categories based on their alcohol
consumption:
1 ) those that drank more than the recommended weekly intake,
i.e. 21 units for men and 14 units for women;
2 ) those that were CAGE positive for alcohol abuse,
i.e. answered yes to at least two of the four CAGE questions (66);
3 ) average total lifetime consumption in units (ATLC).
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DATA ANALYSIS
The multiple objectives of this study necessitated that different types of study
design be employed. The HLA-typing in probands and first degree relatives with
DCM was a cohort analysis defining the frequency of specific HLA regions in
these patients. This could confirm whether certain HLA types were associated
with DCM and whether these types were also predictors of DCM in first degree
relatives.
To examine the relationship of alcohol to dilated cardiomyopathy required
a case-control methodology. One could thus determine whether DCM was
associated with excess alcohol consumption from their alcohol intake by
questionnaire as compared with controls.
The data was entered from pre-coded datasheets (Appendices 1-5,
pages 80-84) onto the mainframe computer for statistical analysis using SAS.





One hundred proband patients with DCM satisfying the usual exclusions and with
angiographically proven coronary arteries attended the special cardiomyopathy
clinic. The clinical characteristics of the probands are summarised in Table 1.
Their age range (mean) was 19-77 (53.5) years, 74 (74%) were male and 34 (34%)
were current smokers. With regards to possible risk factors for DCM, 20 (20%)
reported a viral illness within three months of the diagnosis of DCM, 18 (18%)
had a personal history of atopy and 2 (2%) were peripartum at the time of the
diagnosis.
As detailed below, 56 of the 100 proband families were screened for DCM
and 25 of these 56 families demonstrated a familial tendency for the disease. The
baseline characteristics of these probands were compared with the 31 probands
whose disease was classified as non-familial after screening. Those patients with a
familial tendency to the disease showed a stronger male preponderance than the
non-familial cases (80% vs. 71%; P=0.72). However, the familial cases were no
more likely to report the occurrence of putative risk factors (viral illness, atopy,
pregnancy) for the development ofDCM (Table 2).
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Table 1
Clinical characteristics ofDCM probands (n=100)










NYHA=New York Heart Association functional class; LVEF=left ventricular
ejection fraction; LVIDD=left ventricular internal diastolic diameter
Table 2
Baseline characteristics for the total DCM patient population
compared with familial and non-familial subgroups
Totalpopulation Familial Non-familial
(n=100) (n=25) (n=31)
Mean age (years) 53.5 55 53
Male 74 (74%) 20 (80%) 22 (71%)
Smokers 34 (34%) 8 (32%) 11 (35%)
Viral illness 20 (20%) 4(16%) 7 (23%)
Atopy 18(18%) 4(16%) 6 (19%)
Pregnancy 2 (2%) 0 (0%) 1 (3%)
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A total of 270 first-degree relatives from 75 of the 100 patient families were
potentially available for screening. Twenty-five of the 100 patients either had no
family members available for screening or did not wish their relatives to be
contacted. So far 200 out of a possible total of 270 (74%) first-degree relatives
from 56 out of the 75 (75%) proband families have been screened by
echocardiography. Those not screened include relatives still to be contacted, non-
attenders and those residing abroad.
Of the 56 families screened, 5 (9%) had a first-degree relative already
diagnosed as having DCM and a further 9 (16%) had at least one relative who
fulfilled both echocardiographic criteria for DCM, i.e. a left ventricular ejection
fraction less than 50% and a left ventricular end-diastolic dimension more than
two standard deviations above the mean. Thus, the definite familial occurrence of
DCM in this patient group was 14 / 56 (25%).
In a further 9 families (16%), at least one relative had a possible diagnosis
of DCM, i.e. only one of the two echocardiographic criteria was fulfilled. Six
families (11%) gave a history of premature sudden death, i.e. unexplained at an
age of less than 50 years and within 4 hours of the onset of symptoms, in a first-
degree relative and these were recorded as possible cases of DCM. Thus, an
additional 15 (9+6)/56 (27%) of this patient group demonstrated a familial
tendency to DCM.
Four families had more than one first-degree relative with a definite or
possible diagnosis of DCM. Therefore, the familial prevalence of DCM in this
patient group was definite in 14/56 proband families (25%) and possible in a total
of 25/56 proband families (45%) (Tables 3+4).
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Table 3
Familial prevalence of DCM in 56 proband families screened
Definite DCM : already diagnosed 5 (9%)
both ECHO criteria* 9(16%)
Possible DCM : one of ECHO criteria 9 (16%)
sudden death 6(11%)
Definite familial DCM = 14/56 (25%)
Possible familial DCM = 25/56 (45%)
* LVEF < 50% and LVIDD > 2sd above mean
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Table 4
Familial prevalence of DCM in screened first-degree relatives
Number of relatives / proband family available and screened
Available Screened Familial tendency
1° relatives 270 => 200(74%) => 22(11%)
Proband families 75 => 56 (75%) => 25 (45%)
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HLA-DISTRIBUTION
The HLA-types in the 100 probands were compared with a reference population
of 9000 normal controls from the National Transfusion Service. All halotypes
were checked and significant differences between patients and controls were
restricted to the DR4 subtype.
As compared to controls, the total group of patients with DCM showed no
significant difference in the frequency of the DR4 halotype (32% vs. 39%;
P=0.64). However, when only the DCM probands with a familial tendency were
evaluated, the DR4 subtype was significantly more common in comparison with
the whole patient population (68% vs. 39%; P<0.05) and controls (68% vs. 32%;
P<0.01) (Table 5). Also, within the study group, the proportion of patients with
familial DCM and HLA-DR4 (17/25 (68%)) was significantly higher than the




HLA distribution in DCM patients as compared with controls
DR4 frequency P value
Controls 2880 / 9000 (32%)
DCM probands 39/ 100 (39%) NS
DCM probands* :
non-familial 10/31 (32%) NS
familial 17/25 (68%) <0.01
*56 proband families screened by echocardiography
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HISTOLOGICAL EVALUATION OF BIOPSY SPECIMENS
Diagnostic workup in the first 5 relatives included cardiac catheterization and
right ventricular biopsy (x5). In all 5 cases, coronary arteries were
angiographically normal, as were left and right heart pressures. Histological
evaluation of the right ventricular biopsy specimens revealed mild to moderate
myocyte hypertrophy with only mild or no interstitial fibrosis. There was no
evidence of inflammation (Figure la). The apoptotic index ranged from 17-30%,
with a mean for the 5 cases of 25% (Table 6). TUNEL positive cells were more
prominent in the interstitium than the myocardium (Figure lb). All five biopsy
specimens showed high levels of CPP-32 immunoreactivity (Figure lc). HLA-DR
expression was also detected in all five cases and, as for the evidence of apoptosis,
was more prominent in the interstitium than the myocardium (Figure Id).
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Figure 1.
Representative samples of right ventricular biopsy specimens (x40) from
the five asymptomatic relative with LVE: (a) stained with H+E, showing
mild-to-moderate myocyte hypertrophy, mild-to-no interstitial fibrosis and
no evidence of inflammation; (b) TUNEL staining, showing apoptotic
activity most marked in the interstitium; (c) CPP-32 immunostaining,
showing high levels of activity throughout the biopsy specimen; (d) HLA-
DR immunostaining, showing intense expression, also most marked in the
interstitium.
Table 6
The apoptotic index calculated as the number of TUNEL positive cells
divided by total number of nucleated cells (%) in ten separate high power
(x40) fields per case
Case Total nucleated cells TUNEL positive cells %
1 54±19 14±4 26
2 71±13 21±7 30
3 78+12 11±4 17
4 66±14 19±8 29
5 61+10 15±6 25
Total 66±9 16±4 25±6
(Mean ± standard deviation)
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ALCOHOL CONSUMPTION
Reported alcohol consumption recorded at interview in the 100 patients with
DCM was compared with that of the 211/600 (35%) of randomly selected,
population-based controls who returned their anonymous questionnaire by post.
Significantly more of the 100 patients with DCM than the 211 controls
drank greater than the recommended weekly intake of alcohol (40% vs. 24%;
PO.01) and were alcohol abusers according to the CAGE questionnaire (27% vs.
16%; P<0.05). The age range in cases and controls was similar but the gender
distribution was significantly different. When stratified by gender, the above
differences between cases and controls with regards to alcohol consumption no
longer reached statistical significance (Table 8). For males, the percentage of
cases versus controls drinking alcohol above recommended limits was 40% vs.
30% (P=0.11) and the percentage of alcohol abusers was 33% vs. 22% (P=0.18).
For females, the percentage of cases and controls drinking alcohol above
recommended limits was 30% vs. 19% (P=0.35) and the percentage of alcohol
abusers was 11% vs. 10% (P=0.75).
The average total lifetime consumption (ATLC) measured in units of
alcohol was also significantly greater in cases than controls (31,200 vs. 7,904; P<
0.01). This difference remained significant after gender stratification. The ATLC
in male cases was 51,126 as compared to 10,311 in male controls (P<0.01).
Female ATLC was 14,262 in cases and 6,241 in controls (P<0.05).
The rates of alcohol consumption above recommended weekly limits were
comparable for patients with familial (10/45; 40%) and non-familial (13/31; 42%)
DCM. All the familial cases whose alcohol intake was above recommended limits
were also alcohol abusers according to the CAGE questionnaire, making alcohol




Prevalence of alcohol abuse in DCM cases v Population-based controls






> weekly limit 40 (40%) 50 (24%) <0.01
Cage + ve 27(27%) 33(16%) <0.05
ATLC 31,200 7,904 <0.01
ATLC=average total lifetime consumption (units)
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Table 8

































ATLC=average total lifetime consumption (units)
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Table 9
Prevalence of alcohol abuse in familial v non-familial DCM
Familial Non-familial P value
(n=25) (n=31)
> weekly limit 10(40%) 13(42%) NS
Cage + ve 10(40%) 7(23%) NS
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SCREEN-DETECTED DCM
With regards to the 22 asymptomatic first-degree relatives with left ventricular
enlargement on echocardiographic screening, 18 (82%) were male and the average
age was 40 (range 17-60) years, i.e. younger than the proband population but with
a similar male preponderance. The ECG was abnormal in only 4 (18%) of these
cases, with two patients in atrial fibrillation and two showing non-specific ST
changes.
As was shown for the probands with familial DCM, the screen-detected
relatives were significantly more likely than controls (64% vs. 32%; P<0.01) and
the total patient group (64% vs. 39%; P<0.05) to have the HLA-DR4 subtype.
Compared to population-based controls, they were non-significantly more likely






In this study of patients with DCM, 25% of cases were definitely familial in
nature and a total of 45% showed a familial tendency. Somewhat more surprising
is the 11% frequency of premature sudden death. The majority of patients with
"idiopathic" life-threatening ventricular arrhythmias would appear to have
abnormal myocardium on biopsy (67) and these findings may indicate an early
form of DCM which is too subtle to be detected by usual cardiac investigations.
These results are potentially an underestimate of the prevalence of familial DCM
as not all of the relatives were screened.
It seems likely that left ventricular enlargement, as measured by
echocardiography, in asymptomatic first-degree relatives of probands with DCM
is an early marker of the disease. A recent report from the Framingham Heart
Study demonstrated that an increase in echocardiographic left ventricular
dimension in subjects without a history ofmyocardial infarction or heart failure is
a risk factor for subsequent congestive heart failure (68). The risk-factor-adjusted
hazard ratios for congestive heart failure were 1.47 and 1.43 per increment of one
standard deviation in left ventricular end-diastolic dimension. The study,
involving 4744 men and women with a mean age of 50, identified left ventricular
dimensions as the most important echocardiographic predictor of congestive heart
failure. Thus, it appears that overt ventricular systolic dysfunction is preceded by
an increase in cavity dimensions, with early and asymptomatic left ventricular
dilatation being a subclinical compensatory response to this dysfunction. The
predictive value of left ventricular enlargement in relatives of patients with DCM




One of the earliest discourses on "the non-coronary cardiomyopathies" by
Brigden in 1957 (69) found "strong evidence for familial heart disease" in 7/50
(14%) of cases of isolated heart muscle disease. Numerous studies dating from the
1980's have re-looked at the familial incidence of DCM. The initial work on
familial DCM was retrospective and involved only symptomatic or previously
diagnosed first-degree relatives. The disease was considered familial if at least one
first-degree relative was diagnosed as having DCM and the percentage familial
incidence calculated as that of the total number of probands with one or more
affected relatives. The familial incidence calculated in these studies was generally
low, varying between 2-9% (14,70-74).
In 1992 Michels et al reported a prospective study from the United States,
in which 315 first-degree relatives of 59 patients with DCM were screened by
echocardiography (54). The relatives were diagnosed as having DCM if their left
ventricular ejection fraction was less than 50% and their left ventricular internal
dimension in diastolic was greater than 56 mm. By these criteria 18 relatives from
12 families were shown to have DCM, giving a familial incidence of 12/59 (20%).
The majority of the relatives with DCM were asymptomatic, only 3 having been
previously diagnosed. A study by Zachara et al in 1993 retrospectively calculated,
from previously diagnosed first-degree relatives, a familial incidence of 14 cases
from 105 probands (13%) with DCM (75). They prospectively screened 109
asymptomatic relatives of these 14 cases and identified 23 (21%) potential cases
of DCM based on the same echocardiographic criteria as above. A prospective
study in the United Kingdom found a familial tendency in 10 of 40 (25%) families
ofDCM patients screened (55).
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Pedigree analysis of the potential carriers ofDCM in the latter two studies
revealed a pattern of inheritance consistent with autosomal dominant with
incomplete penetrance (55,75). It is difficult to comment on possible modes of
inheritance in the present study as only first-degree relatives were screened.
However, those families with more than one affected member showed a pattern in
keeping with an autosomal dominant pattern, as previously noted (76.77).
However, others have recorded a recessive or more commonly mixed dominant
and recessive modes of inheritance in familial DCM (54,71,74,78,79). A large
family with X-linked inheritance of DCM has also been described (80). All this
tends to suggest that multiple genetic causes may be responsible for disease
transmission and lead to a final common phenotype in familial DCM.
There have been two separate reports of inherited dilated cardiomyopathy
associated with deletion and mutation of mitochondria (81,82). Such mutations
lead to impaired oxidative phosphorylation, limit the cellular energy available to
cardiac muscle during exercise and, thus, cause myocardial degeneration (83).
Further to this, characteristic electron-microscopic changes have been
demonstrated in myocardial mitochondria from patients with familial
cardiomyopathy (84). Mutation in the muscle promoter region of the dystrophin
gene has also been linked to an X-linked form of familial DCM (85).
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FAMILIAL PREVALENCE
The definite familial prevalence of DCM in this study is similar to those
reported from the USA (86) and the UK (55), showing a 25% occurrence of
familial DCM (Table 10). Obviously, some relatives with a normal echo at one-
off screening may later develop DCM. Only an ongoing prospective study
screening all available first-degree relatives, on a regular basis, would determine
the true prevalence of familial DCM. When sufficient asymptomatic, screen-
detected relatives with DCM are identified, randomised trials of ACE inhibition
and/or immunotherapy to slow disease progression should be initiated.
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Table 10
Familial DCM: prospective screening studies (USA, UK, IRL)
Probands Relatives Familial DCM
Goerrs 1995 (86) 95 457 23 families (24 %)
Keeling 1995 (55) 40 236 10 families (25%)
Present study 56 200 14 families (25%)
Total 191 893 47 (25%)
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HLA-DISTRIBUTION
In this study of patients with DCM, the HLA-type DR4 was significantly more
common in patients with familial DCM than in those with non-familial DCM.
More importantly, HLA-DR4 was associated with over two-thirds (68%) of the
families at risk from DCM. DR4 has been associated with other autoimmune
diseases. The present finding supports an HLA-linked predisposition to the
development of familial DCM. Families of DCM patients with the DR4 subtype
are at particular risk of developing the disease and should probably be screened
regularly by echocardiography, as well as counselled regarding potential lifestyle
and pharmacological interventions which might alter the natural history of the
disease. It is of interest to note that patients undergoing heart transplantation have
less cellular rejection and increased long-term survival if they are HLA-DR
matched with the donor heart (87). This matching process may be of particular
importance in patients with familial DCM being considered for transplantation.
The commonest mechanism cited with regard to the aetiology of DCM,
which relates to the diseases' apparent familial predisposition, is an autoimmune
(HLA-linked) predisposition initiated by an environmental trigger, e.g. viral
illness or alcohol. There are already many well known associations between
diseases with autoimmune features and the human leucocyte histocompatability
(HLA) antigens. HLA links have been made with diseases of presumed viral-
immune origin, e.g. rheumatoid arthritis and lupus erythematosa. The major
histocompatability complex (MHC) plays an important role in presenting antigens
such as a virus to the immune system. Increased expression of the MHC antigens
occurs in tissue undergoing autoimmune destruction.
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Anderson et al in 1984 were the first to report a HLA link in patients with
DCM (50). They found that the HLA types DR4 and B27 were commoner in
patients than controls. The halotype frequency of B27 was 14.5% in patients with
DCM as compared with 3.3% in controls (P=0.001) and that of DR4 was 54% in
DCM and 32% in controls (P=0.02). The HLA-DR4 association with DCM has
since been confirmed by many other studies (88-92) and refuted by one (93). The
latter was a retrospective look at a particular subset of patients who underwent
cardiac transplantation.
Following on from their original retrospective study linking HLA-DR4
with DCM, Anderson's group validated the association in a new set of patients
identified prospectively and in a meta-analysis of five studies comparing the
frequency of HLA-DR antigens in DCM patients (94). They found a DR4
frequency of 20/41 (49%) in patients versus 11/53 (21%) in controls (P<0.005).
They relative risk for DCM with the DR4 subtype was 2.8, with the presence of
this halotype estimated as attributable to one-third of all DCM cases. The meta¬
analysis also indicated a significant increase in the frequency of HLA-DR4 in
patients with DCM, the overall odds ratio for having a DR4 allele being 2.06.
These results supported the belief that predisposing genetic factors linked to
immunoregulation, in conjunction with one of the putative environmental triggers,
may lead to the development of DCM, at least in a subset of patients. The present
study adds considerable weight to this hypothesis by linking the DR4 association,
as a surrogate for autoimmune aetiology, specifically with the subset of DCM
patients with a familial tendency to the disease.
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Normal adult cardiac myocytes express only low levels of MHC class I
and no class II antigens. Human myocarditis is, however, associated with
abnormal myocardial expression of both class I and II MHC antigens (95). This
supports a specific immune-mediated cardiomyopathy in these patients. HLA-DR
expression has also been demonstrated in myocardial biopsy specimens from
patients with DCM (96). Eighty-three of 342 patients (24%) in this study had
HLA-DR expression on the vascular endothelium. The relative odds of
myocardial ischaemia in the biopsy specimens, as measured under electron
microscopy, by the preferential loss of actin over myosin, in DR positive as
compared to DR negative samples were 7.8 (P=0.01). Thus, there appears to be
association between HLA-DR expression and ongoing myocardial ischaemia in
patients with DCM, the location of DR positivity on the vascular endothelium
suggesting that this ischaemia is secondary to microvascular injury. Thus,
exposure to an infectious (viral) or toxic (alcohol) agent may lead to altered HLA-
DR expression in myocardial vascular endothelium. These DR positive cells then,
potentially, initiate an autoimmune response with resulting microvascular injury
and myocardial ischaemia, in a genetically susceptible individual.
The search for humoral markers of autoimmunity in patients with DCM
has been ongoing for the last 20 years. The function of T-cells is to recognise
antigens as foreign , in conjunction with the MHC. Natural killer (NK) leucocytes
are known to be important in host immune surveillance and mediate resistance to
viral infections. NK cell deficiency has been shown to be a disease marker for
DCM and this subgroup of patients with DCM was distinguished from others by
an increase in specific HLA halotypes (97).
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An increase in T-helper/T-suppressor cell ratios has been variably demonstrated in
DCM (98) and is a typical feature of autoimmune disease. Nearly half of patients
with DCM have evidence for a chronic autoimmune process by
immunohistochemical analysis of their cardiac biopsies (99).
Circulating organ-specific cardiac autoantibodies have been demonstrated
in some patients with DCM and been more frequently detected in those patients
with recent onset of disease (51,52). This also suggests a cell-mediated
autoimmune mechanism. The reason for the presence of serological markers in
only some patients with DCM is postulated to be due to either different
aetiologies or a reduction in antibody level with disease progression.
The evidence suggests that DCM can be associated with the host's immune
response and the genetic factors that control this response. It is conceivable that
familial DCM is the subgroup of patients with the disease with, an inherited,
defect in their immune response. This defect may then manifest itself as an
autoantibody directed against the myocardium following an environmental
stimulus, e.g. a viral illness. This theory is lent support by correlations between
specific T-cell gene alleles (100) and HLA-types (101) and the presence of
autoantibodies in familial cardiomyopathy. Organ-specific cardiac antibodies have
also been detected in symptom-free relatives of patients with DCM (52). Once
again implying that the body's autoimmune response , under the control of




Halotype screening may help to elucidate if a genetic predisposition can be
identified in certain family members and, hence, point to a possible pathogenesis
for familial DCM. Hence, those family members with specific MHC genes could
be counselled, advised and followed-up with regard to the possibility of
development of DCM. The presence of circulating autoantibodies does not
adequately distinguish between familial and non-familial DCM (52,102).
If family members at risk from DCM could be identified, early treatment
in the form of ACE inhibition and/or immunotherapy could be tested in a
randomised, controlled with the end-points of ventricular function and mortality
(103). The search for a marker to predict families at risk of developing DCM has
so far been in vain. Perhaps HLA-typing could act as a serum marker to identify
families most likely to benefit from periodic screening with echocardiography and
early treatment when left ventricular dysfunction is detected .
As mentioned already, some relatives with a normal echo at one-off
screening may later develop DCM. Only an ongoing prospective study screening
all available first-degree relatives, on a regular basis, would determine the true
prevalence of familial DCM and the usefulness of markers such HLA-typing in
identifying those families at greatest risk. When sufficient asymptomatic, screen-
detected relatives with DCM are identified, randomised trials of ACE inhibition
and/or immunotherapy to slow disease progression should be initiated.
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Asymptomatic relatives with LVE have active disease which does not appear to be
inflammatory in nature but is associated with a high apoptotic index. Apoptosis,
as measured by TUNEL staining and CPP-32 activity, was more prominent in the
interstitium than the myocardium. The early disease activity was associated with
abnormal HLA-DR expression, again more pronounced within the interstitium.
Little or no fibrosis was evident in the biopsy specimens.
Active myocardial damage without inflammation has previously been
described in symptomatic DCM patients undergoing cardiac transplantation (104).
Apoptosis has been demonstrated in end-stage, ischaemic and non-ischaemic
heart, failure. In this regard, it may be merely a non-specific marker of slow
myocyte loss. More than one method of showing apoptosis is now required to
obtain strong evidence of apoptosis in any human study (105). Narula et al
showed evidence of DNA fragmentation and DNA laddering in explanted hearts
of four patients with idiopathic dilated cardiomyopathy. Only rare apoptosis was
observed in the hearts of four persons who suffered a non-cardiac, sudden death
(57). In contrast to Narula et al, who detected apoptosis mainly in myocytes, we
found apoptosis to be more frequent in the interstitium. It is possible that early
DCM is primarily an interstitial disease, with alteration of the myocardial
interstitium being a primary event in the transition from compensated to
symptomatic heart failure (106).
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Apoptosis has also been shown in 6 of 8 patients with arrhythmogenic
right ventricular, by TUNEL staining and detection of protease CPP-32. The latter
protease is important for the induction of apoptosis in mammalian cells (107).
Apoptosis was prominent in areas with viable myocardium and less frequent in
areas replaced by fat and fibrous tissue (108). Thus, suggesting that the loss of
myocardium through apoptosis may be a primary process, preceding fibrosis in
the absence of an inflammatory response. High levels CPP-32 immunoreactivity
were present in right ventricular myocytes of the six patients. The protease was
undetectable or barely detectable in four control subjects.
Various stimuli may produce TUNEL positive cells within the
myocardium. Myocardial stretch can initiate apoptosis and subsequent impairment
of muscle performance, which can be prevented by the addition of nitric oxide
(NO) releasing drugs (109). The countervailing balance between vasoactive
substances appears to control cell growth and cell death (110). Thus, by inhibiting
vasoconstrictor effects, the homeostatic balance shifts in favor ofNO which may
protect the myocardium from overstretching and apoptotic cell death.
Activation of apoptosis may also be inhibited by expression of the proto-
oncogene bcl2. Olivetti et al examined the hearts of 36 patients with end-stage
heart failure who underwent transplantation. They observed a significant increase
in apoptosis within the myocardium by TUNEL staining and DNA gel
electrophoresis. The percentage ofmyocytes that labeled positively for bcl2 was
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1.8 times higher in patients with cardiac failure, as compared to normal hearts
(56). This suggests that compensatory mechanisms may be initiated in the failing
heart to limit apoptotic cell death and maintain myocardial function.
The presence of p53 in ventricular myocyte cell culture has been shown to
cause a significant increase in transcription of the bax gene, which opposes bcl2
and, hence, promotes apoptosis. The expression of bcl-2 in these cultured
myocytes prevented p53-induced apoptosis. This implies that bcl-2 is an
antiapoptotic agent which may have clinical potential in the overloaded heart
(111).
The cytoplasmic region of the Fas protein is thought to transduce the
intracellular signals required to initiate apoptosis. Patients with the inherited
autoimmune disorder, Canale-Smith syndrome, have mutations in the Fas gene
(112). Such mutations may lead to susceptibility to environmental agents in
autoimmune disorders, for example, viral infection which can activate and induce
programmed cell death in T cells by way of antigen-receptor signaling involving
major histocompatibility complex (MHC) class II antigens (113,114).
MHC class II antigens are expressed mainly on antigen presenting cells of
the immune system and increased expression is present in tissue undergoing
autoimmune injury. Normal myocardium has no detectable levels of MHC class
(including HLA-DR) antigens. Such induction has been demonstrated in the
myocardium and microvascular endothelium ofpatients with active myocarditis,
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with abnormal MHC class I and II antigen expression present in 11/13 patients
and 1/8 controls (88).
The autoimmune hypothesis regarding the etiology of familial DCM is
supported by the increased frequency of HLA-DR4 and the presence of cardiac
autoantibodies in some patients with DCM (50-54,88,90,94,95). We have shown
that the DR4 subtype is significantly more common in familial cases, when
compared to non-familial cases or controls. Thus, there appears to be an HLA
linked predisposition to the development of familial DCM. The expression of
HLA-DR antigen within the myocardium of all the cases in the present study adds
support to the autoimmune hypothesis for familial DCM.
This study shows for the first time that asymptomatic relatives of DCM
patients who demonstrate LVE on echocardiographic screening have ongoing
disease activity. This was evident by mild to moderate myocyte hypertrophy, with
little or no fibrosis and no inflammation in the biopsy samples examined.
Apoptotic activity, as detected by TUNEL activity and CPP-32 immunoreactivity,
and abnormal HLA-DR expression were present in all cases. Interestingly, these
findings were more prominent within the interstitium than the myocardial cells.
Anti-apoptotic therapy may be beneficial at this pre-clinical stage of the disease
process.
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LIMITATIONS
The histological analysis was performed on a small number of right ventricular
biopsy specimens and the interesting observations described must therefore be
viewed as provocative but preliminary. As the previous work cited in the
discussion has shown little or no apoptosis or HLA-DR expression in normal
myocardium, we accepted this as historical control evidence rather than analysing
biopsy specimens obtained from apparently normal myocardium.
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This is the first reported case-control study to compare the alcohol intake of a
group of DCM patients with that of randomly selected, population-based controls.
Both consumption of alcohol above recommended weekly limits (40% vs. 24%;
P<0.01) and alcohol abuse as defined by the CAGE questionnaire^7% vs. 16%;
P<0.05) were significantly more common in patients with DCM than controls.
Those patients with familial DCM were non-significantly more likely than non-
familial probands to be alcohol abusers according to the CAGE questionnaire
(40% vs. 23%; P=0.26). These results support the evidence for alcohol
consumption as an aetiological agent in a minority (20-40%) of patients with
dilated cardiomyopathy. The CAGE questionnaires has a higher predictive value
for identifying alcohol abuse than self-reporting or standard biochemical markers
and it identified 16% of the controls as being alcoholics. Obviously, not all of
these subjects develop dilated cardiomyopathy. The definition of alcoholic heart
muscle disease, hence, over simplifies the relationship between alcohol and heart
failure. To develop alcohol-related dilated cardiomyopathy one must presumably
either be unusually sensitive to its toxic effect and/or develop an immune response
which perpetuates the initial myocardial insult.
Two previous French studies have also demonstrated a greater alcohol
consumption in patients with DCM compared to controls. However, the controls
were patients attending hospital with either surgical complaints (62) or coronary
disease (63). They were, therefore, neither randomly selected nor population-
based, and 50% of them were defined as heavy alcohol consumers. Also, the
numbers of patients and controls in the present case-control study achieved a
higher statistical power than either of the above.
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Assessing alcohol intake, particularly in alcoholics, is notoriously difficult.
The well known CAGE questionnaire gives a sensitivity of 81-91% and
specificity of 77-89% for discriminating between alcoholic and non-alcoholic
patients (66). The negative predictive value of the CAGE questionnaire in the
detection of excessive drinking and alcoholism is 98%. This compares favourably
to the negative predictive value of the biochemical markers gamma-GT and MCV
which are 86% and 84% respectively (115). The most important requirement of a
useful screening test for alcoholism is that it should detect the majority of cases.
In this regard the CAGE questionnaire performs better than biochemical markers
of alcohol intake and will identify nine out of ten alcoholics.
Chronic alcoholism is associated with symptomatic left ventricular
dysfunction in upto one-third of cases (116), with upto two-thirds of
asymptomatic chronic alcoholics demonstrating significant cardiac abnormalities
on echocardiography (117). Large doses of alcohol are, however, required to
demonstrate impaired ventricular function in chronic alcoholics with no preceding
symptoms of cardiac disease (118). Reversibility of this association has also been
demonstrated, with improvement in ventricular function being observed in those
who reduce their alcohol intake or abstain (58,119,120). Although, abstinence
does not guarantee a clinical improvement and myocardial damage may continue
to progress.
Alcohol is negatively inotropic, arrhythmogenic and can cause histological
change in the myocardium in the short term (121). This toxic effect appears to be
dose-related (116) and causative toxins include both ethanol and acetaldehyde




Both ethanol and acetaldehyde inhibit the association of actin and myosin, thus
reducing the contractility of human muscle, in vitro (124). The mechanism of this
inhibition seems to be related both to the binding and uptake of calcium by the
sarcoplasmic reticulum (125) and ATPase activity (126). Another possible
mechanism by which alcohol may cause dilated cardiomyopathy is through
sympathetic overstimulation, with accompanying tachycardia and hypertension
(116,127). Although none of the patients in the present gave a history of
hypertension, one cannot fully exclude the possibility of "burnt-out" hypertensive
heart disease.
The evidence that acute administration of alcohol impairs cardiac function
does not allow the leap of faith to causation in chronic heart failure. There is still
no definitive proof that excess alcohol intake leads to congestive heart failure.
This would require the demonstration of a consistent and progressive damaging
effect of alcohol on myocardial function (128). The evidence linking chronic
alcohol abuse with cardiomyopathy remains, for the most part, conflicting and
circumstantial. The term alcoholic heart muscle disease (AHMD) has been coined
to include those patients with dilated cardiomyopathy who also consume an
arbitrarily set chronic excess amount of alcohol. Their alcohol intake is the only
clinical distinction between these patients and those with a diagnosis of DCM.
There is no proof that excess alcohol is the cause of ventricular dysfunction in
those patients labeled with a diagnosis ofAHMD. Similarly, there is no proof that
alcohol is not involved in the pathogenesis ofDCM in those patients whose intake
is not defined as excessive.
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A myocardial biopsy study of 38 patients with dilated cardiomyopathy
found increased myocardial enzyme activity in the 18 (47%) defined as heavy
drinkers (reported total lifetime consumption greater than 25,000 units) compared
with the rest of the group (129). However, there were no significant differences in
ejection fraction between the two groups. They concluded that, although a
threshold dose of alcohol for heart muscle damage cannot be determined, the
results are "supportive" of an alcoholic aetiology in patients with dilated
cardiomyopathy. The lack of correlation between ejection fraction and alcohol
intake or enzyme activity does, however, somewhat negate this conclusion. By the
same definitions, 7/21 (33%) of heavy drinkers with dilated cardiomyopathy had
circulating antibodies against cardiac protein-acetaldehyde adducts compared with
2/64 (3%) controls (130). The controls were somewhat of a mixed bag of patients:
32 with cardiac failure and an alcohol intake of less than 21 units/week, 22 with
dilated cardiomyopathy and undefined alcohol intake, and 10 with coronary
disease. The result suggests that a minority of heavy drinkers with dilated
cardiomyopathy develop immunogenic cardiac antibodies, which may not only act
as a marker of disease activity but also participate in ongoing heart muscle
damage.
Obrador et al used the hear-to-lung ratio of monoclonal antimyosin
antibodies as a marker of myocardial damage in 117 patients with DCM being
considered for transplantation (131). In this study, 29 (25%) of the patients had a
reported total lifetime alcohol consumption of greater than 36,000 units and were
defined as having "alcoholic dilated cardiomyopathy". This subgroup showed a
significantly less frequent and less intense antibody uptake than the rest of the
patients with dilated cardiomyopathy.
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ALCOHOL CONSUMPTION
Once more, total alcohol intake did not correlate with the echocardiographic
degree of left ventricular dilatation. However, antibody uptake was significantly
higher in present than previous drinkers and abstention was associated with an
increase in ejection fraction. The results suggest that continued alcohol intake
causes chronic left ventricular impairment which is potentially reversible upon
alcohol withdrawal. The antibody response, as for protein-acetaldehyde adducts,
may be a marker of disease activity and/or involved in ongoing immune-mediated
myocardial damage.
Defining patients with dilated cardiomyopathy as having an alcoholic
aetiology on the basis of a cut-off total lifetime intake, whether it be 25,000 or
36,000 units, is convenient for the purposes of a study but an over-simplification.
The above two studies do indicate that chronic alcohol abuse can cause ongoing
myocardial damage which may be of an immune nature. The lack of a dose-
response between total alcohol intake and ejection fraction, however, suggests that
variable sensitivity to its toxic effects, rather than simply lifetime consumption,
determines which alcohol abusers will develop dilated cardiomyopathy. In
contrast to patients with dilated cardiomyopathy who abuse alcohol, subjects
attending hospital primarily for treatment of alcoholism have demonstrated a
negative correlation between ejection fraction and alcohol consumption (116).
This correlation being strongest for total lifetime alcohol intake. Nonetheless, as
discussed by the authors of the latter study, individual susceptibility to myocardial
damage through alcohol abuse clearly varies greatly, with no exact duration of




It is conceivable that even those patients with a low alcohol intake may
have a genetically predisposed greater sensitivity to it's toxic effects (133,134). An
autoimmune process initiated by myocardial necrosis secondary to the toxic
effects of alcohol may be responsible for the continuation of the disease process,
even after long-term abstinence, at least in familial DCM. Alcohol abuse was no
more or less common in familial cases of DCM. Nonetheless it would seem
prudent to advise not only patients but also their first-degree relatives to at least
maintain their alcohol intake within the present recommended weekly limits. It is,
however, important to note that 60% of patients either drank alcohol within the
recommended limits or abstained. This supports the hypothesis that alcohol is




LIMITATIONS OF CASE-CONTROL STUDY
This retrospective determination of alcohol intake was by questionnaire with
potential for recall bias and a reticence to report consumption accurately. Patients
were interviewed and controls returned answers anonymously. This is defended
on the basis of pragmatism and cost. No retest data were generated and no
independent verification of survey responses was sought. Reporting of alcohol
intake is not necessarily any more accurate the second time around. Independent
verification would raise ethical considerations and, also, not necessarily be more
accurate. It may be that interviewing patients resulted in a more honest appraisal
of alcohol consumption. On the other hand, anonymous reporting may enhance
honesty with regards to reporting alcohol intake. While the majority of patients
were male, a larger proportion of the controls were female. When stratified by
gender, only the differences between cases and controls with regards to average
total lifetime consumption of alcohol remained statistically significant. The study
was not powered for subgroup gender analysis. Population-based controls were
selected in favour of other sources of control selection to avoid the risk of over¬
matching for the putative risk factor. Also, the more equal numbers of both sexes
in the control group provides a population-based estimate of alcohol use and
abuse. It is interesting to note that the percentage of the population estimated to be
consuming alcohol above recommended "safe" levels in this Irish study is similar
to The Health of the Nation from the United Kingdom (135). In the latter report,
28% ofmen and 11% ofwomen exceeded 21 and 14 units a week respectively, as
compared to 30% ofmen and 19% ofwomen in the present study.
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SCREEN-DETECTED DCM
As for the probands, the asymptomatic screen-detected relatives with
echocardiography DCM were significantly more likely than controls to have the
DR4 halotype (64% vs. 32%; PO.05). They were also non-significantly more
likely to be alcohol abusers according to the CAGE questionnaire (27% vs. 16%;
P=0.27). This suggests that familial DCM is an autoimmune disease with alcohol
being one of the environmental triggers in a susceptible individual. It is, however,
well known that children born to alcoholics are at increased risk for alcohol abuse
themselves. Therefore, it is possible that part of the familial trend witnessed in
DCM is due to an inherited susceptibility to abuse alcohol. The increased DR4
frequency in these patients does, nonetheless, point to an autoimmune
predisposition to familial DCM. As with the probands with DCM, the majority of
the effected relatives (73%) were not alcohol abusers. Thus, while some of the
screen-detected cases may possibly be the result of familial alcohol abuse alone,
the rest either have an inherited sensitivity to the toxic effects of alcohol or have





The familial prevalence of DCM in this patient group was a 'definite' 25% and a
'possible' 45%. This is the first study to show that familial DCM is linked to the
DR4 halotype, implying an autoimmune predisposition in this subgroup of
patients. The HLA-type DR4 was significantly more common in familial dilated
cardiomyopathy, as compared with non-familial cases and controls, and was
associated with over two-thirds of the families at risk for the disease.
This study shows for the first time that asymptomatic relatives of DCM
patients who demonstrate LVE on echocardiographic screening have ongoing
disease activity. This was evident by mild to moderate myocyte hypertrophy, with
little or no fibrosis and no inflammation in the biopsy samples examined.
Apoptotic activity, as detected by TUNEL activity and CPP-32 immunoreactivity,
and abnormal HLA-DR expression were present in all cases. Interestingly, these
findings were more prominent within the interstitium than the myocardial cells.
This is also the first case-control study to compare alcohol consumption in
a group of DCM patients with that of randomly selected, population-based
controls. Significantly more DCM patients than controls either abuse alcohol or
drink it in excess of recommended limits. Excess alcohol appears to be causally
linked to both familial and non-familial DCM. It is, however, important to note
that 60% of patients either drank alcohol within recommended limits or abstained.
This supports the hypothesis that alcohol is only one ofmany potential triggers for
the development of DCM in a susceptible individual.
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FUTURE RESEARCH AND CLINICAL IMPLICATIONS
The special DCM clinic will continue to recruit patients with DCM and screen as
many of their first-degree relatives as possible, in an attempt to obtain a true
estimate of the familial frequency of the disease. Those first-degree relatives
already "cleared" of having DCM by one-off echocardiography will be recalled
on a regular basis, to better estimate how frequently the disease develops at some
time in family members. In this way, more screen-detected asymptomatic first-
degree relatives will be detected. They will have the diagnosis of DCM confirmed
by excluding the conditions already mentioned and performing angiography to
confirm normal coronary arteries.
The screen-detected patients will be HLA-typed to see if their halotype
distribution corresponds with the original proband diagnosed in that family. Viral
serology will be performed looking for evidence of recent infection (Coxsackie,
Echo) which may have initiated an autoimmune process. Serology will also screen
for cardiac autoantibodies (organ-specific, anti-P, myosin) and specific T-cell
subsets (CD 3,4+8), as further evidence indicating an autoimmune process in the
early stages ofDCM in asymptomatic patients.
The screen-detected DCM cases will undergo exercise testing and VO2
Max to look for early signs of effort limitation. ECG and holter rhythm
monitoring will identify any conduction disturbances or arrhythmias in the early
stages of the disease. At the time of catheterisation the screen-detected patients
will have a right ventricular biopsy performed. Their myocardium can then be
examined for evidence of an autoimmune reaction early in the course of DCM.
This detailed clinical and serological assessment of the asymptomatic screen-
detected patients will give us a better understanding of the exact nature of
autoimmune dysfunction that is present early in the course of familial DCM.
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FUTURE RESEARCH AND CLINICAL IMPLICATIONS
The available evidence suggests that the initial immune response is mainly
humoral and, if the environmental trigger is not eradicated effectively, then a
cellular autoimmune response ensues which is ongoing and leads to further
myocardial damage. It is conceivable that immunotherapy at the early humoral
phase may help the host to eradicate the environmental pathogen, prevent a
cellular response and stop disease progression. Anti-apoptotic therapy, e.g. bcl-2,
may also be beneficial at this pre-clinical stage. Certainly initiation of ACE
inhibitor therapy should slow disease progression by inhibiting further ventricular
remodelling.
When enough cases of early DCM are identified, trials assessing the
effectiveness of the above treatment modalities in altering the natural history of
DCM should be organised. There is a realistic hope that, by detecting and treating





Normal Adult Echocardiographic Measurements (reference 62)
Number
Range Mean
Age (years) 13-54 26 134
Body surface area (m2) 1.45-2.22 1.8 130
LVIDD-flat (mm) 37-56 47 82
LVIDD/m2 (mm) 21-32 26 77








Study No. | | | | 1-3
D.O.B. (dd/mm/yy) j j j j | | | 4-9
Gender (l=m,2 = f) j | 10
Date of last follow-up (dd, mm, yy) | | | | | | | 11-16
Year of diagnosis | | | 17-18
Risk Profile. (l=y,2=n)
Viral Illness {< 3/12 before} | | 19
Peripartum {at diagnosis } | | 20
Atopy | | 21
Cigarettes (no./ d.) at diagnosis | | | 22 - 23
at follow-up j j j 24 - 25
ECHO: {at follow-up}
LVIDD (mm) I 1 I 26 - 27
LVIDS | | 28 - 29
LVEF% (l=normal) I I I 30-31
LVPWD I I I 32 - 33
LVPWS | | | 34 - 35
IVSD 1 j I 36 - 37
IVSS I I i 38 - 39
E/A reversal (l=y,2=n) | | 40
mitral regurg. | | 41
{1 = no, 2 = mild, 3 = mod, 4 = severe}
est. RVSP (mmHg) | | | 42 - 43
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Study No. | | | | 1-3
Study No. ofproband | | | | 4-6
Relation to proband | | 7
(1=sibling,2=parent,3:=child)
D.O.B. (dd/mm/yy) | | | | | | | 8-13
Gender (l=m,2=f) | j 14
ECHO: LVIDD (mm) |_|_| 15-16
LVIDS |_i_| 17-18
LVEF% (l=normal) I I I 19-20
Diagnosis ofDCM | | 21
(l=y,2=n,3=possible)
Yes: EF < 50% and LVIDD > 56 mm
Possible: EF < 50 or LVIDD > 56 mm
If yes to be entered into proband study and be HLA typed .
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Study No. | | | |
D.O.B. (dd/mm/yy) | j | j
Gender (l=m,2=f) j J
Alcohol History
Life-long non-drinker? (l=y,2=n) | |
Age when started | | |
Ex-drinker? (l=y,2=n) j j
Age when stopped | | |
Total duration of drinking (yrs) | | |
Change in intake anytime? | |
Year of change | | |
Ave. weekly intake presently | | | |
(units)
Ave. weekly intake past | | | |
(ex-drinkers, change in intake)
CAGE Questionnaire (l=y,2=n)
Have you ever felt you should | |
cut down on your drinking?
Have people annoyed you by | |
criticising your drinking?
Have you ever felt bad or | |
guilty about your drinking?
Have you ever had a drink | |
first thing in the morning to
steady your nerves or get
rid of a hangover?
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Alcohol questionnaire for randomly selected controls
1. Age (years) =
2. Sex (m/f) =
3. Are you a life-long abstainer from alcohol (non-drinker)? (y/n):
If your answer to Qu.3 is yes, you may leave the rest of the form blank.
4. Ifnot, roughly what age were you when you started to drink? :
5. Are you an ex-drinker ? (y/n):
6. If so, at what age did you stop drinking? (years):
7. Did you change your alcohol consumption at anytime? (y/n):
8. If so, what age were you at that time? (years):
In Qu. 9 + 10, you are asked to express your average weekly alcohol intake in
units. A unit of alcohol is equivalent to half a pint of beer, one measure of spirit or
a glass of wine. Thus, if you drink an average of 10 pints of beer a week that is
equal to 20 units of alcohol etc..
9. What is your present average weekly alcohol intake, in units?
10. If you are an ex-drinker or changed your alcohol intake at sometime,
what was your average weekly intake in the past, in units?
11. Have you ever felt that you should cut down on your drinking? (y/n):
12. Have people ever annoyed you by criticising your drinking? (y/n):
13. Have you ever felt bad or guilty about your drinking? (y/n):
14. Have you ever had a drink first thing in the morning to steady your nerves
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